MacroGenics (MGNX) to Post Earnings on Thursday

Posted by Geri Gentry on Aug 11th, 2026

MacroGenics (NASDAQ:MGNX – Get Free Report) is expected to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect MacroGenics to announce earnings of ($0.0779) per share and revenue of $59.1370 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:00 PM ET.

MacroGenics (NASDAQ:MGNX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.01). The business had revenue of $20.77 million for the quarter, compared to analyst estimates of $15.24 million. MacroGenics had a negative return on equity of 147.80% and a negative net margin of 44.79%. On average, analysts expect MacroGenics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MacroGenics Price Performance

NASDAQ MGNX opened at $4.08 on Tuesday. The stock’s 50-day moving average is $4.23 and its 200-day moving average is $3.33. MacroGenics has a one year low of $1.29 and a one year high of $5.08. The firm has a market cap of $259.32 million, a P/E ratio of -3.71 and a beta of 1.20.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MacroGenics in a research report on Wednesday, August 5th. Barclays raised their price objective on MacroGenics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, MacroGenics has an average rating of “Hold” and an average price target of $5.50.

View Our Latest Stock Analysis on MacroGenics

Hedge Funds Weigh In On MacroGenics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd bought a new position in shares of MacroGenics in the third quarter valued at about $38,000. Engineers Gate Manager LP bought a new stake in shares of MacroGenics during the 2nd quarter worth about $28,000. Walleye Capital LLC acquired a new position in MacroGenics in the 2nd quarter valued at about $30,000. Cresset Asset Management LLC grew its stake in MacroGenics by 52.3% in the 2nd quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 9,172 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new position in MacroGenics in the 2nd quarter valued at about $33,000. 96.89% of the stock is owned by institutional investors.

About MacroGenics

(Get Free Report)

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.